---
schema_version: "secwatch.filing_event.v1"
accession: "0001062822-23-000045"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T07:05:06.147139+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lexicon reports Q2 net loss $44.9M; FDA-approved INPEFA launched, LX9211 advancing

## Summary
- FDA approved INPEFA (sotagliflozin) for heart failure across full LVEF range; U.S. launch completed within 30 days.
- LX9211 moving into late-stage development for DPNP; Phase 2b dose optimization study starts Q3 2023.
- Q2 2023 net loss of $44.9M ($0.22 per share) vs $24.6M ($0.16) in Q2 2022.
- SG&A expenses rose to $30.0M from $10.7M due to commercial launch preparations; R&D $14.5M vs $13.4M.
- Cash and investments $256.7M as of June 30, 2023, up from $138.4M at Dec 31, 2022.

## SEC filing metadata
- accession: 0001062822-23-000045
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000106282223000045/0001062822-23-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000106282223000045/lxrx-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062822-23-000045
- JSON: https://secwatch.observer/filing/0001062822-23-000045.json
- Plain text: https://secwatch.observer/filing/0001062822-23-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.